TransThera Sciences (Nanjing), Inc. (HKG:2617)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Development of Innovative Medicines	1.18M	124.00K
Total	1.18M	124.00K

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Mainland China	7.00K	-
Republic of Korea	1.17M	124.00K
Total	1.18M	124.00K

Data Source: S&P Global Market Intelligence Last updated: Sep 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 1, 2026

Data Sources Report a data error